Geely Auto Entrusts WAT Medical to Develop Neuromodulation Technologies to Improve Travel Experiences
Geely Holding Group is committed to becoming a globally competitive and influential smart electric mobility and energy service technology company, with businesses covering automotive upstream and downstream industry chains, smart mobility services, green transportation, and digital technology. Though the electrification and intelligent transformation of the automobile industry, Geely has built a technological moat and strengthened the technological ecosystem in cutting-edge fields such as new energy technologies, shared travel, Internet of Vehicles, intelligent driving, and in-vehicle chips. Geely is among the top ten global auto brand ranked in portfolio value, and aims to create a travel experience that exceeds user expectations with high-quality and technologically advanced products. Geely Group acquired all shares of Volvo Cars in August 2010.
WAT Medical develops innovative home medical devices through targeted neuromodulation technology. With more than 70 patents around the world, there are advanced R&D and design centers in North America, production bases in China that conform to the quality control systems of medical devices in various countries. WAT Medical's anti-motion sickness wristbands and migraine treatment devices are sold in more than 30 countries, and have entered the US and Denmark's medical insurance reimbursement catalogs. Co-founder Peter Ji won the 2021 Innovation Award from the University of California, Berkeley.
With over 12 years of experience and intellectual property in the field of targeted neuromodulation, WAT Medical develops automotive-grade neuromodulation products for Geely Group. The project will use medicine, engineering, materials science, and computer technology across multiple disciplines to provide solutions to prevent fatigue driving and motion sickness to elevate the travel experience according to automotive industry standards.